Cholesterol Metabolism in Pancreatic Cancer
Cancers · 27.10.2023 · 15 (21) · 5177
DOI: 10.3390/cancers15215177 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.10.2023. Verfasst von Artur Rebelo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Visceral, Vascular and Endocrine Surgery, University Medical Center Halle, Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germ…. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Advanced Clinician Scientist Program of Medical Faculty of the Martin‑Luther University Halle‑Wittenberg, Halle (Saale), Germany, Advanced Clinician Scientist Program of the Medical Faculty of the Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany.
Abstract (Originalsprache)
Pancreatic cancer’s substantial impact on cancer-related mortality, responsible for 8% of cancer deaths and ranking fourth in the US, persists despite advancements, with a five-year relative survival rate of only 11%. Forecasts predict a 70% surge in new cases and a 72% increase in global pancreatic cancer-related deaths by 2040. This review explores the intrinsic metabolic reprogramming of pancreatic cancer, focusing on the mevalonate pathway, including cholesterol biosynthesis, transportation, targeting strategies, and clinical studies. The mevalonate pathway, central to cellular metabolism, significantly shapes pancreatic cancer progression. Acetyl coenzyme A (Acetyl-CoA) serves a dual role in fatty acid and cholesterol biosynthesis, fueling acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN) development. Enzymes, including acetoacetyl-CoA thiolase, 3-hydroxy-3methylglutaryl-CoA (HMG-CoA) synthase, and HMG-CoA reductase, are key enzymes in pancreatic cancer. Inhibiting HMG-CoA reductase, e.g., by using statins, shows promise in delaying PanIN progression and impeding pancreatic cancer. Dysregulation of cholesterol modification, uptake, and transport significantly impacts tumor progression, with Sterol O-acyltransferase 1 (SOAT1) driving cholesterol ester (CE) accumulation and disrupted low-density lipoprotein receptor (LDLR) expression contributing to cancer recurrence. Apolipoprotein E (ApoE) expression in tumor stroma influences immune suppression. Clinical trials targeting cholesterol metabolism, including statins and SOAT1 inhibitors, exhibit potential anti-tumor effects, and combination therapies enhance efficacy. This review provides insights into cholesterol metabolism’s convergence with pancreatic cancer, shedding light on therapeutic avenues and ongoing clinical investigations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Visceral, Vascular and Endocrine Surgery, University Medical Center Halle, Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany.
ORCID-Profile: Artur Rebelo, Jörg Kleeff, Yoshiaki Sunami
Förderung
- Advanced Clinician Scientist Program of Medical Faculty of the Martin‑Luther University Halle‑Wittenberg, Halle (Saale), Germany
- Advanced Clinician Scientist Program of the Medical Faculty of the Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany
Zitieren
APA
Rebelo, A., Kleeff, J., & Sunami, Y. (2023). Cholesterol Metabolism in Pancreatic Cancer. Cancers, 15(21), 5177. https://doi.org/10.3390/cancers15215177
Vancouver
Rebelo A, Kleeff J, Sunami Y. Cholesterol Metabolism in Pancreatic Cancer. Cancers. 2023;15(21):5177. doi:10.3390/cancers15215177
BibTeX
@article{Rebelo2023,
author = {Rebelo, Artur and Kleeff, Jörg and Sunami, Yoshiaki},
title = {Cholesterol Metabolism in Pancreatic Cancer},
journal = {Cancers},
year = {2023},
volume = {15},
number = {21},
pages = {5177},
doi = {10.3390/cancers15215177}
}
EUVIMED